<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949818</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx2011-4</org_study_id>
    <nct_id>NCT01949818</nct_id>
  </id_info>
  <brief_title>Treatment of Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Yangzhengxiaoji Capsule
      Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to the date of death (approximately 5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Yangzhengxiaoji Capsule combined with CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yangzhengxiaoji capsule combined with CHOP regimen</intervention_name>
    <description>Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.</description>
    <arm_group_label>Yangzhengxiaoji Capsule combined with CHOP regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
    <description>CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5</description>
    <arm_group_label>CHOP regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time &gt; 3
        months Histological confirmed Diffuse large B cell lymphoma(III/IV) None of chemotherapy or
        radiotherapy has been previously used None of chemotherapy contraindication: hemoglobin ≥
        90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin
        ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L At
        least one measurable lesion None of other serious diseases, cardiopulmonary function is
        normal Pregnancy test of women at reproductive age must be negative Patients could be
        followed up None of other relative treatments including the traditional Chinese medicine,
        immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic
        treatments.

        Exclusion Criteria:

          -  Disagreement on blood sample collection Patients allergic of any of drug in this
             regimen or with metabolic disorder Pregnant or lactating women Serious medical illness
             likely to interfere with participation Serious infection Primitive or secondary tumors
             of central nervous system Chemotherapy or radiotherapy contraindication The evidence
             of CNS metastasis History of peripheral nervous disorder or dysphrenia patients
             participating in other clinical trials patients taking other antitumor drugs patients
             estimated to be unsuitable by investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi Zhang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi Zhang, Dr</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhanf, Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Mingzhi Zhang, Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>The director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

